|
Name |
[(1R,2R,3Z,5R,7S,9Z,11R,12S,14R,15S,16R,17S)-17-benzyl-5-hydroxy-5,7,14,15-tetramethyl-19-oxo-13-oxa-18-azatetracyclo[9.8.0.01,16.012,14]nonadeca-3,9-dien-2-yl] acetate
|
Molecular Formula | C30H39NO5 | |
IUPAC Name* |
[(1R,2R,3Z,5R,7S,9Z,11R,12S,14R,15S,16R,17S)-17-benzyl-5-hydroxy-5,7,14,15-tetramethyl-19-oxo-13-oxa-18-azatetracyclo[9.8.0.01,16.012,14]nonadeca-3,9-dien-2-yl] acetate
|
|
SMILES |
C[C@H]1C/C=C\[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2([C@@H](/C=C\[C@](C1)(C)O)OC(=O)C)C(=O)N[C@H]4CC5=CC=CC=C5)C)C
|
|
InChI |
InChI=1S/C30H39NO5/c1-18-10-9-13-22-26-29(5,36-26)19(2)25-23(16-21-11-7-6-8-12-21)31-27(33)30(22,25)24(35-20(3)32)14-15-28(4,34)17-18/h6-9,11-15,18-19,22-26,34H,10,16-17H2,1-5H3,(H,31,33)/b13-9-,15-14-/t18-,19-,22-,23-,24+,25-,26-,28-,29+,30+/m0/s1
|
|
InChIKey |
QHZKOXCMCJMHJE-ILIZJMQPSA-N
|
|
Synonyms |
Epoxycytochalasin H; NCGC00247576-01; 96639-05-3
|
|
CAS | NA | |
PubChem CID | 53316350 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 493.6 | ALogp: | 3.9 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 88.2 | Aromatic Rings: | 5 |
Heavy Atoms: | 36 | QED Weighted: | 0.365 |
Caco-2 Permeability: | -4.968 | MDCK Permeability: | 0.00002870 |
Pgp-inhibitor: | 0.971 | Pgp-substrate: | 0.69 |
Human Intestinal Absorption (HIA): | 0.029 | 20% Bioavailability (F20%): | 0.476 |
30% Bioavailability (F30%): | 0.412 |
Blood-Brain-Barrier Penetration (BBB): | 0.821 | Plasma Protein Binding (PPB): | 75.01% |
Volume Distribution (VD): | 1.025 | Fu: | 22.05% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.117 |
CYP2C19-inhibitor: | 0.668 | CYP2C19-substrate: | 0.727 |
CYP2C9-inhibitor: | 0.733 | CYP2C9-substrate: | 0.074 |
CYP2D6-inhibitor: | 0.055 | CYP2D6-substrate: | 0.159 |
CYP3A4-inhibitor: | 0.911 | CYP3A4-substrate: | 0.452 |
Clearance (CL): | 6.347 | Half-life (T1/2): | 0.864 |
hERG Blockers: | 0.416 | Human Hepatotoxicity (H-HT): | 0.833 |
Drug-inuced Liver Injury (DILI): | 0.372 | AMES Toxicity: | 0.196 |
Rat Oral Acute Toxicity: | 0.256 | Maximum Recommended Daily Dose: | 0.886 |
Skin Sensitization: | 0.229 | Carcinogencity: | 0.057 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.01 |
Respiratory Toxicity: | 0.948 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003653 | 0.827 | D06CWH | 0.276 | ||||
ENC002261 | 0.827 | D05VQI | 0.270 | ||||
ENC002202 | 0.820 | D0V3ZA | 0.260 | ||||
ENC004468 | 0.761 | D0R1BD | 0.254 | ||||
ENC005133 | 0.748 | D01TSI | 0.253 | ||||
ENC002828 | 0.739 | D09NNH | 0.253 | ||||
ENC001922 | 0.728 | D0SP3D | 0.253 | ||||
ENC003331 | 0.725 | D0TB8C | 0.247 | ||||
ENC002763 | 0.701 | D0W7RJ | 0.245 | ||||
ENC001886 | 0.667 | D07HOF | 0.244 |